BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wingerchuk DM, Fujihara K, Palace J, Berthele A, Levy M, Kim HJ, Nakashima I, Oreja-Guevara C, Wang KC, Miller L, Shang S, Sabatella G, Yountz M, Pittock SJ; PREVENT Study Group. Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD. Ann Neurol 2021;89:1088-98. [PMID: 33586143 DOI: 10.1002/ana.26049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Hartung HP. Neuromyelitis Optica Spectrum Disorder: Therapeutic Innovations and Complex Decision-Making. Ann Neurol 2021;89:1084-7. [PMID: 33871885 DOI: 10.1002/ana.26087] [Reference Citation Analysis]
2 Rensel M, Zabeti A, Mealy MA, Cimbora D, She D, Drappa J, Katz E. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial. Mult Scler 2021;:13524585211047223. [PMID: 34595983 DOI: 10.1177/13524585211047223] [Reference Citation Analysis]
3 Kadish R, Clardy SL, Royston M, Tanvir I, Parker T, Biskupiak J, Kielhorn A. Clinical burden of relapses in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder: A single center cohort analysis. J Neuroimmunol 2022;362:577761. [PMID: 34823121 DOI: 10.1016/j.jneuroim.2021.577761] [Reference Citation Analysis]
4 Molazadeh N, Filippatou AG, Vasileiou ES, Levy M, Sotirchos ES. Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorder. J Neuroimmunol 2021;360:577702. [PMID: 34547512 DOI: 10.1016/j.jneuroim.2021.577702] [Reference Citation Analysis]
5 McCombe JA, Pittock SJ. Anti-complement Agents for Autoimmune Neurological Disease. Neurotherapeutics 2022. [PMID: 35553024 DOI: 10.1007/s13311-022-01223-w] [Reference Citation Analysis]
6 Bhagavati S. Autoimmune Disorders of the Nervous System: Pathophysiology, Clinical Features, and Therapy. Front Neurol 2021;12:664664. [PMID: 33935958 DOI: 10.3389/fneur.2021.664664] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Pittock SJ, Zekeridou A, Weinshenker BG. Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials. Nat Rev Neurol 2021. [PMID: 34711906 DOI: 10.1038/s41582-021-00568-8] [Reference Citation Analysis]
8 Giglhuber K, Berthele A. Adverse Events in NMOSD Therapy. IJMS 2022;23:4154. [DOI: 10.3390/ijms23084154] [Reference Citation Analysis]
9 Chen Y, Chu JMT, Chang RCC, Wong GTC. The Complement System in the Central Nervous System: From Neurodevelopment to Neurodegeneration. Biomolecules 2022;12:337. [PMID: 35204837 DOI: 10.3390/biom12020337] [Reference Citation Analysis]